Background {#Sec1}
==========

Dermatological diseases are relatively common in diabetic patients, in which they manifest cutaneously as a variety of conditions such as bacterial and fungal infections, diabetic dermopathy, granuloma annulare, and necrobiosis lipoidica diabeticorum \[[@CR1]\]. Bullosis diabeticorum is a rare cutaneous disease, with 100 cases or case series reported in the literature \[[@CR2]\], characterized by spontaneous noninflammatory manifestations, painless subcutaneous fluid-filled vesicles varying in size from a few millimeters to a few centimeters. It is usually distributed in the lower extremities, in which there is an observed risk of developing secondary infection, including diabetic skin ulcer (Fig. [1a](#Fig1){ref-type="fig"}), osteomyelitis (Fig. [1b](#Fig1){ref-type="fig"}), or wet gangrene (Fig. [1c](#Fig1){ref-type="fig"}), even diabetic amputation. Presently the exact etiology of bullosis diabticorum is not well understood. Several studies revealed that its occurrence is closely related to diabetic patients with complications of microangiopathy \[[@CR3]\], neuropathy, and poor regulation of blood glucose \[[@CR4]\]. Bullosis diabeticorum is not uncommon in our clinical experience and observation; an average of 250 people with diabetes per year with foot problems (skin disease, ulcer, gangrene) were treated in the past 10 years, including about 60 cases with bullosis diabticorm. Thus, there is a bullosis diabeticorum incidence rate of 2.4% per year in our clinic. Bullosis diabticorum is prone to occur in patients with local microcirculation dysfunction (Fig. [2a](#Fig2){ref-type="fig"}-[d](#Fig2){ref-type="fig"}) and diabetic neuropathy (Fig. [2e](#Fig2){ref-type="fig"}-[h](#Fig2){ref-type="fig"}). Often, conservative treatment is often considered, while aggressive surgical debridement and subsequently skin grafting are indicated in more severe cases \[[@CR5]\]. Moreover, the elimination of causative factors is imperative for prevention of its recurrence and complications \[[@CR4], [@CR5]\]. In our previous study, we successfully treated diabetic critical limb ischemia with bone marrow mesenchymal stem cells (BMMSCs) \[[@CR6], [@CR7]\]. To further explore their benefits, we have administered BMMSC transplantation therapy to a patient with recurrent bullosis diabeticorum in the left lower limb complicated by limb ischemia and mild venous insufficiency.Fig. 1**a** Bullosis diabeticorum with skin ulcer. **b** Bullosis diabticorum with diabetic osteomyelitis. **c** Bullosis diabeticorum with wet gangreneFig. 2**a**-**d** Ischemic bullosis diabeticorum. **e**-**h** Neuropathic bullosis diabeticorum

Methods {#Sec2}
=======

Patient {#Sec3}
-------

A 64-year-old male presented to hospital in July 2004 for the sudden occurrence of cutaneous blisters of varying sizes with associated signs and symptoms of cellulitis in the left lateral lower limb, including erythema, edema, increased skin temperature, and tenderness. In May 2005, the patient was re-admitted to the hospital with similar signs and symptoms in the left lower limb when he was diagnosed with diabetes mellitus based on fasting serum glucose level and 2-h postprandial serum glucose (10.06 mmol/L and 14.6 mmol/L, respectively), even though he was not aware of having diabetes mellitus prior to this admission. In addition, this patient had a medical history of hypertension and was previously a smoker. In the following 2 years, the patient had four other hospital admissions due to recurring episodes of cutaneous blistering at the same anatomical location. During the physical examination, multiple clear fluid-filled vesicles of variable dimensions were observed in the left lower limb, surrounded by subcutaneous cellulitis (Fig. [3d](#Fig3){ref-type="fig"}). The fluid within bullae was aspirated and cultured; it showed no bacterial growth, consistent with the literature for the diagnosis of bullosis diabeticorum \[[@CR3], [@CR4]\].Fig. 3Bone marrow mesenchymal stem cell (BMMSC) transplantation procedure. **a** Extraction of bone marrow under disinfected and anesthetic conditions. **b** The mononuclear stem cell layer was harvested with density gradient centrifugation. **c** BMMSC morphology after 21 days of culture. **d** Subcutaneous cellulitis with bullosis diabeticorum. **e** Administration of BMMSCs with normal saline. **f** The left lower limb 10 years after BMMSC treatment

Assessments {#Sec4}
-----------

Peripheral vascular assessment was performed to establish the vascular status in the bilateral lower extremities. Pedal pulses, both the posterior tibialis and the dorsalis pedis artery, were found to be palpable and regular. The left and right ankle brachial index (ABI) was 0.72 and 0.85, respectively. Lower extremity ultrasound revealed atheromatous plaque formation in the tunica intima of the left femoral and popliteal artery, and atherosclerotic plaque formation in the anterior wall of the left femoral artery. Doppler ultrasound demonstrated no vascular abnormalities in major vessels of the left lower limb. Evaluation of the bilateral peripheral arterial system was also achieved with magnetic resonance angiography (MRA). There were no abnormalities in the bilateral internal iliac, external iliac, and femoral artery, except for vessel wall thickening of the left femoral and perforating arteries and enlargement of the left posterior tibial artery. Venography of the left lower limb showed delay in the venous return compared to the contralateral limb. Plain X-ray showed no soft tissue swelling and no bony cortical erosion or periosteal reaction and no subcutaneous gas or osteomyelitis was detected. Combined with the clinical assessments and literature review, recurrent bullosis diabeticorum and cellulitis could be associated with lower limb ischemia and venous stasis. Diabetic neuropathy was excluded through nerve conduct velocity, a gold standard for diagnosis of diabetic neuropathy.

Preparation of BMMSCs {#Sec5}
---------------------

With reference to our previous research technique \[[@CR6]\], 30 ml bone barrow was extracted from the patient under aseptic and anesthetic conditions (Fig. [3a](#Fig3){ref-type="fig"}). Mononuclear stem cells were isolated using density gradient centrifugation (Fig. [3b](#Fig3){ref-type="fig"}). The harvested autologous BMMSCs, with a total cell count of 7.8 × 10^7^, were cultured with alpha-modified minimum essential medium (α-MEM; Invitrogen-Life Technologies Corp., USA) supplemented with 10% autologous serum. The culture medium was replaced every 3 days. Once approximately 70% confluence was achieved, the cultured stem cells were resuspended in trypsin-EDTA. Cells with an approximately adjusted cell density of 4000 cells per cm^2^ were transferred once every 5 days. The above procedures were done in accordance with the criteria for cell transplantation: (1) negative results of the microbiological tests; (2) endotoxin content of ≤ 5 EU/kg patient body weight; and (3) cell viability of ≥ 95% \[[@CR6]\].

Transplantation procedure and follow-up results {#Sec6}
-----------------------------------------------

At the same time, the bullae were de-roofed to drain the wound fluid and uncover the underlying wound bed. After which, the wound was dressed with appropriate wound dressing and the patient received combination antibiotics therapy. As we described in a previous study \[[@CR6]\], the harvested autologous BMMSCs amount to 8.6 × 10^8^ cells suspended in normal saline after 21 days of culture at three passages (Fig. [3c](#Fig3){ref-type="fig"}). Subsequently, the prepared BMMSCs, without cryopreservation, were injected into the left calf muscle with 1 cm intervals after the local infection had subsided (Fig. [3e](#Fig3){ref-type="fig"}). Nine months after treatment, the patient developed another episode of bullosis diabeticorum with accompanying cellulitis in the same lower limb and they were successfully treated similarly tot he previous measures. At a 10-year follow-up period, the patient reported no recurrence of bullosis diabeticorum in the left lower limb (Fig. [3f](#Fig3){ref-type="fig"}). Peripheral vascular assessment was performed again in October 2017 and the left and right ABI was 1.03 and 0.89, respectively.

Discussion {#Sec7}
==========

Without history of trauma, skin manifestations have been suggested to be probable cutaneous markers for early detection of overt diabetes or prediabetes \[[@CR1], [@CR8]\]. As has been reported, bullosis diabecticorum could precede the diagnosis of diabetes mellitus \[[@CR8]\], consistent with our reported case. Bullosis diabecticorum is also commonly known as diabetic bullous disease, which is a rare, spontaneous, and non-inflammatory diabetic complication with an incidence rate of 0.16% \[[@CR9]\]. The pathogenesis is largely ambiguous, with some researchers believing that a long duration of microvascular disease results in skin dystrophy with capillary basement membrane thickening, which eventually leads to blister formation with tissue hypoxia and microcirculation ischemia \[[@CR10]\]. The predisposition to develop bullosis diabeticorum, as we learnt from this case, seems to be associated with varying degrees of limb ischemia. Notably, both Doppler ultrasonography and magnetic resonance angiography showed that this patient had suffered multiple vascular stenoses in the lower extremity. Previous studies have revealed that peripheral arterial disease (PAD) of the lower limb was one of significant and independent risk factors for diabetic foot infection \[[@CR10], [@CR11]\]. Therefore, lower extremity cellulitis followed by bullosis diabecticorum was considered as a complication of diabetic PAD in this case.

So far as we know, there is no clinical practice guidance for the appropriate treatment of bullosis diabeticorum. Based on the case findings and literature reports, appropriate management of lower limb ischemia is fundamental for preventing its recurrence. Conventionally, the treatment of severe ischemic lower extremity vascular disease mainly involves both medical and/or early revascularization intervention, either endovascular or open surgery. In some cases, pharmacotherapy alone could not fully address the lower limb ischemia while open surgery or endovascular treatment is contradicted in others due to pre-existing cardiovascular and cerebrovascular diseases. In this case, the patient declined any revascularization treatment but was willing to try conservative treatment. As such, the novel cell therapy was assigned to this patient to eradicate its potential recurrence. Since 2005, our team has been dedicated to the therapeutic use of different stem cells for diabetic wound repair and limb salvage \[[@CR6], [@CR7], [@CR12]--[@CR14]\]. Both BMMSCs and bone marrow-derived mononuclear cells have been used for diabetics with critical limb ischemia and foot ulcer, the former producing better clinical outcomes \[[@CR6]\]. In a basic study, we explored the regulatory mechanism of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) and found that it could enhance engraftment and angiogenesis of mesenchymal stem cells \[[@CR7]\]. In another study by Wang et al., the authors observed that PGC-1α also regulates the expression of B-cell lymphoma/leukemia-2 (Bcl-2) and stimulates the survival of mesenchymal stem cells via PGC-1α--ERRα interaction without the influence of serum, hypoxia, and high glucose conditions \[[@CR15]\]. In addition, adipose-derived stem cells were also employed for the regulation of diabetic microenvironment \[[@CR13]\].

In view of the above theoretical and practical experience, autologous BMMSCs were isolated, cultured, and transplanted into the patient's left ischemic lower extremities. Other than one reported recurrence at 9 months, bullosis diabeticorum and the associated cellulitis went into remission after transplantation therapy in the following 10 years. In a meta-analysis study by Rigato et al., they showed that cell therapy reduced the risk of amputation by 37% and improved limb salvage by 18% and wound healing by 59%. Cell therapy also significantly increased ABI and transcutaneous oxygen pressure and reduced rest pain \[[@CR16]\]. We speculated that the effects of transplanted stem cells might be gradual, starting from cellular differentiation, proliferation, and formation of new capillaries, and eventually improve the lower limb blood flow. At the start of the therapy period, formation of capillary networks and establishment of collateral circulation would not be adequate in ischemic tissue, which may induce another recurrence of bullosis diabecticorum. As blood flow and lower limb ischemia improve, the occurrence slowly tapers off. Thus, stem cell therapy provides an additional, viable option for patients who are ineligible for revascularization procedures. In another meta-analysis study by Fadini et al., the authors reported that traditional revascularization is not suitable for more than one-third of patients and these may benefit from stem cell therapies \[[@CR17]\].

Conclusions {#Sec8}
===========

This case describes a patient with a repeated blister disease and cellulitis that were resistant to various treatment modalities but eventually improved with the application of autologous BMMSCs. Autologous bone marrow cell therapy is a feasible, safe, and potentially effective therapeutic strategy for PAD patients who are considered unsuitable candidates for traditional revascularization. This case highlights the potential effect of autologous BMMSCs to relieve repeated cellulitis and blister disease. Early identification of diabetes and its complications and appropriate treatment may improve clinical outcomes and prevent lower limb amputation.
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